The Diabetes congress represents latest approaches for prevention and treatments of DM type 2. The congress was held on January 5th, 2017 by Iran Endocrine Society about the latest updates in managing diabetes which was headed up by Dr.Hashemi, a chairperson of Iran Endocrine Society of Shahid Beheshti University. All well-known companies in diabetes field were present at the congress.
APOTEX team represented Apo-Metformin as the first line treatment of oral anti-hyperglycemic drug with the least side effects accessible in Iran pharmaceutical market. Physicians showed their interest in returning Apo-Metformin to Iran.